A Phase 3 interventional study of Iron isomaltoside/ferric derisomaltose and Iron sucrose in Iron Deficiency Anaemia, Iron Deficiency Anemia and Chronic Kidney Disease, sponsored by Pharmacosmos A/S. Completed at 141 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-10-06.
Sponsored by Pharmacosmos A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies testing iron isomaltoside 1000 in Anemia, Iron-Deficiency — 9 open to participants now, 9 under way, 4 of them phase 3. iron isomaltoside 1000 · Anemia, Iron-Deficiency.
Among the 32 studies testing iron isomaltoside 1000 in Anemia, Iron-Deficiency, this one is the 2nd largest by enrollment, is one of 4 that started in 2016, is one of 18 in phase 3, and was the 8th registered.
601 studies on the registry are indexed under Anemia, Iron-Deficiency; 96 are open to participants now.
Browse Anemia, Iron-Deficiency studies →9 of the 32 studies testing iron isomaltoside 1000 in Anemia, Iron-Deficiency are open now, in 6 countries. Recruiting first, the newest first:
Sichuan Huiyu Pharmaceutical Co., Ltd · Sites in China
Ages 18+
Hull University Teaching Hospitals NHS Trust · Sites in United Kingdom
Ages 18+
AHS Cancer Control Alberta · Sites in Canada
Ages 18+ · Women only
Children's Hospital Los Angeles · Sites in United States
Ages 16–60 · Women only · Healthy volunteers
Sun Yat-sen University · Sites in China
Ages 18–65
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 55 Anemia, Iron-Deficiency studies recruiting now, 19 (35%) set no upper age limit and 32 (58%) stop at 75 or younger; 16 take children under 18; 17 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 3 · Phase 3 19 · Phase 4 7
First in 2007; this study’s year is marked. 4 started in 2016.
This study's enrollment of 1,538 is above the median of 100 across 460 interventional studies indexed under Anemia, Iron-Deficiency.
Median enrollment 121 across the 32 interventional studies. Of the 19 that completed or were terminated, 8 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 32 have an industry lead sponsor. The 10 most frequent:
Pharmacosmos A/S is the lead sponsor of 36 studies on the registry; 5 are open to participants now.
15 studies in Anemia, Iron-Deficiency by Pharmacosmos A/S: none open now, none under way, none of them phase 3. Of 14 finished, 7 (50%) have results posted.
Among the 15 studies in Anemia, Iron-Deficiency by Pharmacosmos A/S, this one has the largest enrollment of the 13 interventional ones that give a count, is one of 3 that started in 2016, is one of 11 in phase 3, and was the 9th registered.
Pharmacosmos A/S’s Anemia, Iron-Deficiency studies by the year they started, since 2007.
3 of the studies testing iron isomaltoside 1000 in Anemia, Iron-Deficiency that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05462704Phase 3Women and Infants Hospital of Rhode IslandIntravenous Versus Oral Iron for Treating Iron-Deficiency Anemia in Pregnancy | 2027-03-30 |
| NCT06884280Phase 3Hull University Teaching Hospitals NHS TrustComparing High and Low Dose Iron Treatments for People on Peritoneal Dialysis: The PALaDIN Study | 2027-10 |
| NCT04913649dr. P. NoordzijIntravenous Iron to Treat Postoperative Anemia in Older Cardiac Surgery Patients | 2026-11 |
Add all 3 to your calendar (.ics) → With an account.
Among the 32 studies testing iron isomaltoside 1000 in Anemia, Iron-Deficiency, from their registry updates:
Among Pharmacosmos A/S’s 15 in Anemia, Iron-Deficiency:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Evaluation of safety and efficacy of iron isomaltoside/ferric derisomaltose compared with iron sucrose, in subjects with both non-dialysis-dependent chronic kidney disease (NDD-CKD) and iron deficiency anaemia (IDA).
Iron deficiency anaemia (IDA) is a common problem associated with many chronic diseases such as chronic kidney disease (CKD). IDA can have a substantial medical and quality of life (QoL) burden on the subjects. Therapy of these subjects includes treating the underlying cause of IDA and restoring haemoglobin (Hb) concentration and iron stores.
This study evaluated the safety and efficacy of iron isomaltoside/ferric derisomaltose compared with iron sucrose in subjects with both non-dialysis-dependent chronic kidney disease (NDD-CKD) and iron deficiency anaemia (IDA).
The study subjects received either a single intravenous (IV) dose of iron isomaltoside/ferric derisomaltose (1000 mg at baseline) or iron sucrose (200 mg IV injections at baseline and repeated according to standard practice or physician choice up to a maximum of five times within the first two weeks starting at baseline; a cumulative dose of 1000 mg was recommended). The study subjects were monitored for up to 8 weeks from baseline.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria includes:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Administered IV
Drug: Iron isomaltoside/ferric derisomaltose
Administered IV
Drug: Iron sucrose
Drug page: Iron isomaltoside 1000
Iron isomaltoside/ferric derisomaltose (Monofer®/Monoferric®; 100 mg/mL) was the test product in this trial. The dose of iron isomaltoside/ferric derisomaltose for the individual subject was set to 1000 mg. The dose was diluted in 100 mL 0.9 % sodium chloride (100 mL bags) and administered as a single IV infusion over approximately 20 minutes.
Also known as: Monofer®, Monoferric®, Monover®, Monofar®, Monoferro®
Iron sucrose (Venofer®; 20 mg elemental iron/mL) was the comparator in this trial. Iron sucrose was administered as 200 mg undiluted IV injections over approximately 2-5 minutes and repeated according to standard practice or physician choice up to a maximum of five times within the first two weeks starting at baseline. A cumulative dose of 1000 mg was recommended.
Also known as: Venofer®
Change in Hemoglobin (Hb) From Baseline to Week 8
Efficacy Evaluate the effect of iron isomaltoside/ferric derisomaltose vs iron sucrose in subjects with non-dialysis-dependent chronic kidney disease (NDD-CKD) and iron deficiency anaemia (IDA). Response was defined as change from baseline in hemoglobin (Hb) to week 8, i.e. ability to increase Hb in subjects with NDD-CKD and IDA, when oral iron preparations were ineffective or could not be used, or in whom the Hb measurement at screening in Investigators' opinion were sufficiently low to require rapid repletion of iron stores.
Time frame: Baseline to week 8
Incidence of Protocol-defined Serious or Severe Hypersensitivity Reactions
Safety For this endpoint, the number of participants with serious or severe hypersensitivity reactions were evaluated. The hypersensitivity reactions that were included in the analysis were those that started on or after the first dose of randomised treatment (i.e. treatment emergent). The terms used to define hypersensitivity were those specified by the Standardised MedDRA Queries (SMQ) for hypersensitivity, plus four additional terms: loss of consciousness, seizure, syncope, unresponsiveness. The potential hypersensitivity AEs were adjudicated in a blinded fashion by an independent Clinical Endpoint Adjudication Committee (CEAC). Results show only those participants that had adjudicated and confirmed serious or severe hypersensitivity reactions.
Time frame: Baseline to week 8
Composite Cardiovascular Adverse Events (AEs)
Safety Results show the composite cardiovascular AEs, that started on or after the first dose of randomised treatment (i.e. treatment emergent) up to week 8. The reported potential cardiovascular AEs were adjudicated in a blinded fashion by an independent Clinical Endpoint Adjudication Committee (CEAC). The potential cardiovascular AEs included the following: * Death due to any cause * Non-fatal myocardial infarction * Non-fatal stroke * Unstable angina requiring hospitalisation * Congestive heart failure requiring hospitalisation or medical intervention * Arrhythmias * Hypertension * Hypotension Results show only those participants that had adjudicated and confirmed treatment-emergent composite cardiovascular AEs.
Time frame: Baseline, week 1, 2, and 8
Time to First Composite Cardiovascular Safety AE
Safety Time to first composite cardiovascular AE was defined as the actual time in days from first dose of treatment until the date of the composite cardiovascular AE. For subjects not reporting a composite cardiovascular AE, the time was censored at the date of the last attended visit. Only the adjudicated and confirmed composite cardiovascular safety AEs, as judged by the CEAC, were considered for this endpoint. Time to first composite cardiovascular AE was defined as the actual time in days from first dose of treatment until the date of the composite cardiovascular AE. For subjects not reporting a composite cardiovascular AE, the time was censored at the date of the last attended visit.
Time frame: Baseline, week 1, 2, 4, and 8
S-phosphate <2 mg/dL at Any Time From Baseline to Week 1, 2, 4, and 8
Safety Results show the number of participants who had s-phosphate \<2 mg/dL at any time from baseline to week 1, 2, 4, or 8.
Time frame: Baseline, week 1, 2, 4, and 8
Hb Concentration Increase of ≥1 g/dL From Baseline to Week 1, 2, 4, and 8
Efficacy Results show Hb responders to the treatment. A subject was considered a Hb responder to a certain week if an increase in Hb of at least 1 g/dL from baseline to the week in question was observed (from baseline to week 1, 2, 4, and 8).
Time frame: Baseline, week 1, 2, 4, and 8
Time to Change in Hb Concentration ≥1 g/dL
Efficacy Time to change in Hb concentration ≥1 g/dL. Subjects who showed Hb concentration increase of ≥1 g/dL (from baseline to week 1, 2, 4, and 8). For responders, time to Hb response was defined as the scheduled time from baseline until the visit where the first Hb response was measured.
Time frame: Baseline, week 1, 2, 4, and 8
Hb Concentration of >12 g/dL at Any Time From Week 1 to Week 8
Efficacy Hb concentration of \>12 g/dL at any time from week 1 to week 8. Results show the number of participants who achieved Hb concentration of \>12 g/dL at any time from week 1 to week 8.
Time frame: Week 1 to week 8
Hb Concentration Increase of ≥2 g/dL at Any Time From Week 1 to Week 8
Efficacy Results show the number of participants who achieved Hb concentration increase of ≥2 g/dL at any time from week 1 to week 8.
Time frame: Week 1 to week 8
S-Ferritin Concentration of ≥100 ng/mL and Transferrin Saturation (TSAT) of 20-50% at Any Time From Week 1 to Week 8
Efficacy Proportion of subjects reaching the composite endpoint of s-ferritin concentration ≥100 ng/mL and TSAT of 20-50% at any time from week 1 to 8.
Time frame: Week 1 to week 8
Change in Hb Concentration From Baseline to Week 1, 2, and 4
Efficacy Change in Hb concentration from baseline to week 1, 2, and 4.
Time frame: Baseline, week 1, 2, and 4
Change in S-ferritin From Baseline to Weeks 1, 2, 4, and 8
Efficacy Changes in s-ferritin from baseline to weeks 1, 2, 4, and 8.
Time frame: Baseline, week 1, 2, 4, and 8
Change in Transferrin Saturation (TSAT) From Baseline to Week 1, 2, 4, and 8
Efficacy Changes in transferrin saturation (TSAT) from baseline to week 1, 2, 4, and 8.
Time frame: Baseline, week 1, 2, 4, and 8
Change in Concentration of S-iron From Baseline to Week 1, 2, 4, and 8
Efficacy Changes in the concentrations of serum iron (s-iron) from baseline to week 1, 2, 4, and 8.
Time frame: Baseline, week 1, 2, 4, and 8
Change in Fatigue Symptoms From Baseline to Week 1, 2, and 8
Efficacy Change in fatigue symptoms from baseline to week 1, 2, and 8 was measured by the Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Scale. The Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Scale consisted of 13 items ranging from 0 (not at all) to 4 (very much), except items #7 and #8 which are reversed scored. The total score range is 0-52. A score of less than 30 indicated severe fatigue, and the higher the score, the better outcome/quality of life (QoL). If more than 50% of the items for a subject at a given visit were missing, the total score was not calculated. Total score was calculated as shown below: Total score= Sum of individual scores x 13 / Number of items answered
Time frame: Baseline, week 1, 2, and 8
Intervals in Screening for Diabetic Retinopathy (ISDR) Questionnaire, Cost of Public Transport/Taxi And Parking
Pharmacoeconomics The Intervals in Screening for Diabetic Retinopathy (ISDR) questionnaire at the baseline visit assessed the resources used by subjects to receive treatment. Resources used on other trial activities were not included. ISDR responses were summarised using descriptive statistics. The data for this endpoint show the responses at baseline for both treatment groups. The frequency of drug administration between the 2 treatment groups is different, however, (i.e. up to a factor 5 in the iron sucrose treatment group).
Time frame: Baseline
Intervals in Screening for Diabetic Retinopathy (ISDR) Questionnaire, Return Journey by Car
Pharmacoeconomics The Intervals in Screening for Diabetic Retinopathy (ISDR) questionnaire at the baseline visit assessed the resources used by subjects to receive treatment. Resources used on other trial activities were not included. ISDR responses were summarised using descriptive statistics. The data for this endpoint show the responses at baseline for both treatment groups. The frequency of drug administration between the 2 treatment groups is different, however, (i.e. up to a factor 5 in the iron sucrose treatment group).
Time frame: Baseline
Intervals in Screening for Diabetic Retinopathy (ISDR) Questionnaire, Time Spent on Visit/Helping on Visit
Pharmacoeconomics The Intervals in Screening for Diabetic Retinopathy (ISDR) questionnaire at the baseline visit assessed the resources used by subjects to receive treatment. Resources used on other trial activities were not included. ISDR responses were summarised using descriptive statistics. The data for this endpoint show the responses at baseline for both treatment groups. The frequency of drug administration between the 2 treatment groups is different, however, (i.e. up to a factor 5 in the iron sucrose treatment group).
Time frame: Baseline
Intervals in Screening for Diabetic Retinopathy (ISDR) Questionnaire, Participants/Others Who Took Time Off Work to Attend Visits
Pharmacoeconomics The Intervals in Screening for Diabetic Retinopathy (ISDR) questionnaire at the baseline visit assessed the resources used by subjects to receive treatment. Resources used on other trial activities were not included. ISDR responses were summarised using descriptive statistics. The data for this endpoint show the responses at baseline for both treatment groups. The frequency of drug administration between the 2 treatment groups is different, however, (i.e. up to a factor 5 in the iron sucrose treatment group).
Time frame: Baseline
Health Care Resource Use Questionnaire
Pharmacoeconomics Resources used by the health care staff (per administration), measured by the health care resource use questionnaire. The questionnaire assessed the time used by the health care staff during administration of the investigational product and the administration time (including the observational time). The health care participants included in the evaluation were: investigator, pharmacist, physician, study coordinator, study nurse. The data for this endpoint show the responses at baseline for both treatment groups. The frequency of drug administration between the 2 treatment groups is different (i.e. up to a factor 5 more frequent in the iron sucrose treatment group).
Time frame: Baseline
A total of 2560 subjects were screened and 1538 subjects were randomised into the trial.
| Milestone | Iron Isomaltoside/Ferric Derisomaltose | Iron Sucrose |
|---|---|---|
| Started | 1027 | 511 |
| Completed | 971 | 476 |
| Not completed | 56 | 35 |
| Withdrew: Non-serious ae | 1 | 2 |
| Withdrew: Serious ae | 7 | 3 |
| Withdrew: Withdrawal by subject | 19 | 9 |
| Withdrew: Lost to follow-up | 13 | 7 |
| Withdrew: Physician decision | 5 | 3 |
| Withdrew: Sponsor decision | 0 | 1 |
| Withdrew: Protocol violation | 0 | 2 |
| Withdrew: Death | 3 | 2 |
| Withdrew: Moved, poor venous access, transport | 6 | 4 |
| Withdrew: Not treated | 2 | 2 |
Efficacy Evaluate the effect of iron isomaltoside/ferric derisomaltose vs iron sucrose in subjects with non-dialysis-dependent chronic kidney disease (NDD-CKD) and iron deficiency anaemia (IDA). Response was defined as change from baseline in hemoglobin (Hb) to week 8, i.e. ability to increase Hb in subjects with NDD-CKD and IDA, when oral iron preparations were ineffective or could not be used, or in whom the Hb measurement at screening in Investigators' opinion were sufficiently low to require rapid repletion of iron stores.
| g/dL | Iron Isomaltoside/Ferric Derisomaltose | Iron Sucrose |
|---|---|---|
| Change in Hemoglobin (Hb) From Baseline to Week 8 | 1.22 (1.14 to 1.31) | 1.14 (1.03 to 1.26) |
Safety For this endpoint, the number of participants with serious or severe hypersensitivity reactions were evaluated. The hypersensitivity reactions that were included in the analysis were those that started on or after the first dose of randomised treatment (i.e. treatment emergent). The terms used to define hypersensitivity were those specified by the Standardised MedDRA Queries (SMQ) for hypersensitivity, plus four additional terms: loss of consciousness, seizure, syncope, unresponsiveness. The potential hypersensitivity AEs were adjudicated in a blinded fashion by an independent Clinical Endpoint Adjudication Committee (CEAC). Results show only those participants that had adjudicated and confirmed serious or severe hypersensitivity reactions.
| Participants | Iron Isomaltoside/Ferric Derisomaltose | Iron Sucrose |
|---|---|---|
| Incidence of Protocol-defined Serious or Severe Hypersensitivity Reactions | 3 | 0 |
Safety Results show the composite cardiovascular AEs, that started on or after the first dose of randomised treatment (i.e. treatment emergent) up to week 8. The reported potential cardiovascular AEs were adjudicated in a blinded fashion by an independent Clinical Endpoint Adjudication Committee (CEAC). The potential cardiovascular AEs included the following: * Death due to any cause * Non-fatal myocardial infarction * Non-fatal stroke * Unstable angina requiring hospitalisation * Congestive heart failure requiring hospitalisation or medical intervention * Arrhythmias * Hypertension * Hypotension Results show only those participants that had adjudicated and confirmed treatment-emergent composite cardiovascular AEs.
| Participants | Iron Isomaltoside/Ferric Derisomaltose | Iron Sucrose |
|---|---|---|
| Composite Cardiovascular Adverse Events (AEs) | 42 | 35 |
Safety Time to first composite cardiovascular AE was defined as the actual time in days from first dose of treatment until the date of the composite cardiovascular AE. For subjects not reporting a composite cardiovascular AE, the time was censored at the date of the last attended visit. Only the adjudicated and confirmed composite cardiovascular safety AEs, as judged by the CEAC, were considered for this endpoint. Time to first composite cardiovascular AE was defined as the actual time in days from first dose of treatment until the date of the composite cardiovascular AE. For subjects not reporting a composite cardiovascular AE, the time was censored at the date of the last attended visit.
| Week | Iron Isomaltoside/Ferric Derisomaltose | Iron Sucrose |
|---|---|---|
| Time to First Composite Cardiovascular Safety AE | NA (NA to NA) | NA (NA to NA) |
Safety Results show the number of participants who had s-phosphate \<2 mg/dL at any time from baseline to week 1, 2, 4, or 8.
| Participants | Iron Isomaltoside/Ferric Derisomaltose | Iron Sucrose |
|---|---|---|
| S-phosphate <2 mg/dL at Any Time From Baseline to Week 1, 2, 4, and 8 | 32 | 4 |
Efficacy Results show Hb responders to the treatment. A subject was considered a Hb responder to a certain week if an increase in Hb of at least 1 g/dL from baseline to the week in question was observed (from baseline to week 1, 2, 4, and 8).
| Participants | Iron Isomaltoside/Ferric Derisomaltose | Iron Sucrose |
|---|---|---|
| Responder YES week 1 | 200 | 78 |
| Responder YES week 2 | 339 | 112 |
| Responder YES week 4 | 430 | 174 |
| Responder YES week 8 | 474 | 226 |
Efficacy Time to change in Hb concentration ≥1 g/dL. Subjects who showed Hb concentration increase of ≥1 g/dL (from baseline to week 1, 2, 4, and 8). For responders, time to Hb response was defined as the scheduled time from baseline until the visit where the first Hb response was measured.
| Days | Iron Isomaltoside/Ferric Derisomaltose | Iron Sucrose |
|---|---|---|
| Time to Change in Hb Concentration ≥1 g/dL | 56 (28 to 56) | 56 (28 to NA) |
Efficacy Hb concentration of \>12 g/dL at any time from week 1 to week 8. Results show the number of participants who achieved Hb concentration of \>12 g/dL at any time from week 1 to week 8.
| Participants | Iron Isomaltoside/Ferric Derisomaltose | Iron Sucrose |
|---|---|---|
| Hb Concentration of >12 g/dL at Any Time From Week 1 to Week 8 | 259 | 121 |
Efficacy Results show the number of participants who achieved Hb concentration increase of ≥2 g/dL at any time from week 1 to week 8.
| Participants | Iron Isomaltoside/Ferric Derisomaltose | Iron Sucrose |
|---|---|---|
| Hb Concentration Increase of ≥2 g/dL at Any Time From Week 1 to Week 8 | 307 | 133 |
Efficacy Proportion of subjects reaching the composite endpoint of s-ferritin concentration ≥100 ng/mL and TSAT of 20-50% at any time from week 1 to 8.
| Participants | Iron Isomaltoside/Ferric Derisomaltose | Iron Sucrose |
|---|---|---|
| S-Ferritin Concentration of ≥100 ng/mL and Transferrin Saturation (TSAT) of 20-50% at Any Time From Week 1 to Week 8 | 873 | 388 |
Efficacy Change in Hb concentration from baseline to week 1, 2, and 4.
| g/dL | Iron Isomaltoside/Ferric Derisomaltose | Iron Sucrose |
|---|---|---|
| Week 1 | 0.44 ± 0.94 | 0.21 ± 1.02 |
| Week 2 | 0.77 ± 1.16 | 0.50 ± 1.15 |
| Week 4 | 1.08 ± 1.32 | 0.90 ± 1.33 |
Efficacy Changes in s-ferritin from baseline to weeks 1, 2, 4, and 8.
| ng/mL | Iron Isomaltoside/Ferric Derisomaltose | Iron Sucrose |
|---|---|---|
| Week 1 | 492.4 ± 309.7 | 183.9 ± 129.4 |
| Week 2 | 381.2 ± 283.8 | 292.4 ± 210.4 |
| Week 4 | 258.4 ± 214.5 | 255.4 ± 265.6 |
| Week 8 | 191.3 ± 196.1 | 187.9 ± 210.6 |
Efficacy Changes in transferrin saturation (TSAT) from baseline to week 1, 2, 4, and 8.
| percent | Iron Isomaltoside/Ferric Derisomaltose | Iron Sucrose |
|---|---|---|
| Week 1 | 12.10 ± 31.99 | 4.31 ± 23.10 |
| Week 2 | 5.84 ± 29.79 | 5.64 ± 14.35 |
| Week 4 | 4.99 ± 30.00 | 5.59 ± 12.31 |
| Week 8 | 5.10 ± 30.17 | 5.93 ± 12.86 |
Efficacy Changes in the concentrations of serum iron (s-iron) from baseline to week 1, 2, 4, and 8.
| μg/dL | Iron Isomaltoside/Ferric Derisomaltose | Iron Sucrose |
|---|---|---|
| Week 1 | 34.8 ± 99.7 | 11.1 ± 71.1 |
| Week 2 | 11.1 ± 90.6 | 12.4 ± 44.1 |
| Week 4 | 6.5 ± 91.2 | 10.2 ± 38.3 |
| Week 8 | 7.1 ± 91.3 | 12.4 ± 41.9 |
Efficacy Change in fatigue symptoms from baseline to week 1, 2, and 8 was measured by the Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Scale. The Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Scale consisted of 13 items ranging from 0 (not at all) to 4 (very much), except items #7 and #8 which are reversed scored. The total score range is 0-52. A score of less than 30 indicated severe fatigue, and the higher the score, the better outcome/quality of life (QoL). If more than 50% of the items for a subject at a given visit were missing, the total score was not calculated. Total score was calculated as shown below: Total score= Sum of individual scores x 13 / Number of items answered
| score on a scale | Iron Isomaltoside/Ferric Derisomaltose | Iron Sucrose |
|---|---|---|
| Week 1 | 5.04 ± 8.85 | 5.01 ± 7.93 |
| Week 2 | 7.29 ± 9.84 | 7.63 ± 9.74 |
| Week 8 | 9.13 ± 11.09 | 9.07 ± 11.40 |
Pharmacoeconomics The Intervals in Screening for Diabetic Retinopathy (ISDR) questionnaire at the baseline visit assessed the resources used by subjects to receive treatment. Resources used on other trial activities were not included. ISDR responses were summarised using descriptive statistics. The data for this endpoint show the responses at baseline for both treatment groups. The frequency of drug administration between the 2 treatment groups is different, however, (i.e. up to a factor 5 in the iron sucrose treatment group).
| US dollars ($) | Iron Isomaltoside/Ferric Derisomaltose | Iron Sucrose |
|---|---|---|
| Cost of public transport/taxi | 0.0 (0 to 87) | 0.0 (0 to 46) |
| Cost of parking | 0.0 (0 to 45) | 0.0 (0 to 25) |
Pharmacoeconomics The Intervals in Screening for Diabetic Retinopathy (ISDR) questionnaire at the baseline visit assessed the resources used by subjects to receive treatment. Resources used on other trial activities were not included. ISDR responses were summarised using descriptive statistics. The data for this endpoint show the responses at baseline for both treatment groups. The frequency of drug administration between the 2 treatment groups is different, however, (i.e. up to a factor 5 in the iron sucrose treatment group).
| miles | Iron Isomaltoside/Ferric Derisomaltose | Iron Sucrose |
|---|---|---|
| Intervals in Screening for Diabetic Retinopathy (ISDR) Questionnaire, Return Journey by Car | 19.0 (0 to 232) | 18.0 (0 to 240) |
Pharmacoeconomics The Intervals in Screening for Diabetic Retinopathy (ISDR) questionnaire at the baseline visit assessed the resources used by subjects to receive treatment. Resources used on other trial activities were not included. ISDR responses were summarised using descriptive statistics. The data for this endpoint show the responses at baseline for both treatment groups. The frequency of drug administration between the 2 treatment groups is different, however, (i.e. up to a factor 5 in the iron sucrose treatment group).
| Hours | Iron Isomaltoside/Ferric Derisomaltose | Iron Sucrose |
|---|---|---|
| Time spent on visit | 2.00 (0.0 to 6.3) | 2.00 (0.0 to 6.0) |
| Total time spent helping on visit | 2.00 (0.0 to 6.3) | 2.00 (0.0 to 10.5) |
Pharmacoeconomics The Intervals in Screening for Diabetic Retinopathy (ISDR) questionnaire at the baseline visit assessed the resources used by subjects to receive treatment. Resources used on other trial activities were not included. ISDR responses were summarised using descriptive statistics. The data for this endpoint show the responses at baseline for both treatment groups. The frequency of drug administration between the 2 treatment groups is different, however, (i.e. up to a factor 5 in the iron sucrose treatment group).
| Participants | Iron Isomaltoside/Ferric Derisomaltose | Iron Sucrose |
|---|---|---|
| In employment, YES | 152 | 57 |
| Took time off work to attend, YES | 70 | 26 |
| Assistance by others to attend visit, YES | 410 | 197 |
| Others took time off work to attend, YES | 82 | 40 |
Pharmacoeconomics Resources used by the health care staff (per administration), measured by the health care resource use questionnaire. The questionnaire assessed the time used by the health care staff during administration of the investigational product and the administration time (including the observational time). The health care participants included in the evaluation were: investigator, pharmacist, physician, study coordinator, study nurse. The data for this endpoint show the responses at baseline for both treatment groups. The frequency of drug administration between the 2 treatment groups is different (i.e. up to a factor 5 more frequent in the iron sucrose treatment group).
| hours | Iron Isomaltoside/Ferric Derisomaltose | Iron Sucrose |
|---|---|---|
| Time spent per site staff | 1.17 (0.0 to 20.8) | 1.00 (0.0 to 20.1) |
| Time spent per subject | 2.58 (0.5 to 20.8) | 2.33 (0.2 to 20.3) |
Collected over From the time a subjects had signed the informed consent form (CRF) and until they had completed the study, all adverse events (AEs) or serious adverse events (SAEs) were reported in the CRF. The actual study duration was 8 weeks (or shorted if the trial was discontinued). Overall, eligible subjects participated in the trial for approximately 10 weeks (including a 14-day screening period).. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Iron Isomaltoside/Ferric Derisomaltose | 3/1,019 (0.3%) | 83/1,019 (8.1%) | 56/1,019 (5.5%) |
| Iron Sucrose | 3/506 (0.6%) | 50/506 (9.9%) | 34/506 (6.7%) |
| Event | Iron Isomaltoside/Ferric Derisomaltose | Iron Sucrose |
|---|---|---|
| Cardiac failure congestiveCardiac disorders | 7/1019 | 11/506 |
| Acute kidney injuryRenal and urinary disorders | 7/1019 | 5/506 |
| Chronic kidney diseaseRenal and urinary disorders | 5/1019 | 3/506 |
| CellulitisInfections and infestations | 1/1019 | 3/506 |
| Chest painGeneral disorders | 2/1019 | 3/506 |
| End stage renal diseaseRenal and urinary disorders | 5/1019 | 2/506 |
| Atrial fibrillationCardiac disorders | 1/1019 | 2/506 |
| Cardiac arrestCardiac disorders | 1/1019 | 2/506 |
| Urinary tract infectionInfections and infestations | 3/1019 | 2/506 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 2/1019 | 2/506 |
| Event | Iron Isomaltoside/Ferric Derisomaltose | Iron Sucrose |
|---|---|---|
| Urinary tract infectionInfections and infestations | 22/1019 | 14/506 |
| HypertensionVascular disorders | 14/1019 | 13/506 |
| HyperkalaemiaMetabolism and nutrition disorders | 22/1019 | 9/506 |
| Age, Continuous(years) | Iron Isomaltoside/Ferric Derisomaltose | Iron Sucrose | Total |
|---|---|---|---|
| Mean | 68.3 ± 12.3 | 69.3 ± 12.3 | 68.6 ± 12.3 |
| Age, Customized(participants) | Iron Isomaltoside/Ferric Derisomaltose | Iron Sucrose | Total |
|---|---|---|---|
| Between 18 and 65 years | 337 | 151 | 488 |
| 65-84 years | 608 | 316 | 924 |
| > 84 years | 82 | 44 | 126 |
| Sex: Female, Male(Participants) | Iron Isomaltoside/Ferric Derisomaltose | Iron Sucrose | Total |
|---|---|---|---|
| Female | 633 | 329 | 962 |
| Male | 394 | 182 | 576 |
| Ethnicity (NIH/OMB)(Participants) | Iron Isomaltoside/Ferric Derisomaltose | Iron Sucrose | Total |
|---|---|---|---|
| Hispanic or Latino | 476 | 248 | 724 |
| Not Hispanic or Latino | 551 | 263 | 814 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Iron Isomaltoside/Ferric Derisomaltose | Iron Sucrose | Total |
|---|---|---|---|
| American Indian or Alaska Native | 2 | 2 | 4 |
| Asian | 16 | 11 | 27 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
| Black or African American | 264 | 117 | 381 |
| White | 731 | 375 | 1106 |
| More than one race | 2 | 0 | 2 |
| Unknown or Not Reported | 11 | 6 | 17 |
| Race/Ethnicity, Customized(participants) | Iron Isomaltoside/Ferric Derisomaltose | Iron Sucrose | Total |
|---|---|---|---|
| Mexican | 4 | 3 | 7 |
| Indigenous Mexican | 1 | 0 | 1 |
| Mixed (Caucasian and Native american) | 1 | 0 | 1 |
| Hispanic | 4 | 3 | 7 |
| Central Indian | 1 | 0 | 1 |
| Guyanese | 1 | 0 | 1 |
| Other (Mixed: not declared) | 1 | 0 | 1 |
| Region of Enrollment(participants) | Iron Isomaltoside/Ferric Derisomaltose | Iron Sucrose | Total |
|---|---|---|---|
| United States | 1027 | 511 | 1538 |
| Current smoker(participants) | Iron Isomaltoside/Ferric Derisomaltose | Iron Sucrose | Total |
|---|---|---|---|
| YES | 118 | 53 | 171 |
| NO | 909 | 458 | 1367 |
Showing the first 100 of 141 sites. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Nov 2016 to primary completion in May 2018, 18 months.
Results were first posted in Mar 2020, 1 year 9 months after primary completion. A results delay was requested in May 2019.
Of 49 phase 3 interventional studies under Anemia, Iron-Deficiency, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 18 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Iron isomaltoside 1000